CD4+ T cells, especially MOG-specific CD4+ T cells, from patients with MS expressed low amounts of RNF157 and showed elevated levels of TBX21 (T-bet), RORC (RORγt), IFNG, and IL17A, compared with CD4+ T cells from HC (Figure 1C). This evidence concerns the gene IL17A and myeloid sarcoma.